Anixa Biosciences, Inc. (ANIX): Investors Should Ignore the Haters And Buy

As volatility creeps into Anixa Biosciences, Inc. (NASDAQ:ANIX), investors need to pay close attention to to the factors affecting stock today as its shares are trading 2.47% or 0.113 points down from last closing price of $4.55, reaching $4.4375 at last check. The ANIX share price is losing for the second day in a row and has dropped in 3 of the last 5 days and is up 7.82% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -195,640 shares, and in total 82960 shares valued at $368135 were seen changing hands compared with 278600 shares valued at $1.268 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the ANIX stock is near its bottom.

Anixa Biosciences, Inc. (ANIX) shares have notched a 3-month gain of about 7.82%, but has still advanced 15.48% year to date. By comparison, the stock added 43.53% over the past 12 months, while it jumped 9.9% over the 1 month. The company’s market cap is around $94.28M, with its short interest ratio standing at 13.57%.

In the current trading session for ANIX, the stock witnessed two major price actions, it rose to a high of $4.59 and was down as much as $4.28 at one point. The high recorded is very low when compared to their 52-week high which is $3.1. The 52-week high is now at -35.9 distance from current price. Their recent low of $6.86 represents a 41.87% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ANIX is $11.25, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Anixa Biosciences, Inc. earned $-0.96 per share in the trailing 12 months and has a P/E ratio of -4.62. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 95.83 and lower compared to the sector’s average of 34.03. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ANIX also has P/S multiple of 153.24. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 41.87x.

ANIX‘s last price was down -0.03% as compared to the average trading price of 50 days recorded at $4.44 while enlarging the period to 200 trading days, the average closing price was $4.13. At present, there are 20.72 million in the total number of common shares owned by the public and among those 18.29 million shares have been available to trade. The percentage of shares being held by the company management was 5.6% while institutions stake was 6.4%. The company has generated negative returns on equity over the last 12 months (-306.1%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the ANIX stock, there is another set of technicals that should be looked into and considered. Its 12.67% gain from moving average of $3.94 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0.72 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

In the last five years, the EPS of the company has been roughly 9.1%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 23.4 over the last five years. The company recently recorded a drop of -62.5%, but this figure is rather unattractive.